181 related articles for article (PubMed ID: 22899554)
1. Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120.
Chen W; Kaplan BL; Pike ST; Topper LA; Lichorobiec NR; Simmons SO; Ramabhadran R; Kaminski NE
J Leukoc Biol; 2012 Nov; 92(5):1093-102. PubMed ID: 22899554
[TBL] [Abstract][Full Text] [Related]
2. Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol.
Chen W; Crawford RB; Kaplan BL; Kaminski NE
J Neuroimmune Pharmacol; 2015 Jun; 10(2):344-55. PubMed ID: 25900076
[TBL] [Abstract][Full Text] [Related]
3. Interferon-
Henriquez JE; Rizzo MD; Crawford RB; Gulick P; Kaminski NE
J Pharmacol Exp Ther; 2018 Oct; 367(1):49-58. PubMed ID: 30026298
[TBL] [Abstract][Full Text] [Related]
4. Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.
Lombard C; Hegde VL; Nagarkatti M; Nagarkatti PS
J Pharmacol Exp Ther; 2011 Nov; 339(2):607-17. PubMed ID: 21831965
[TBL] [Abstract][Full Text] [Related]
5. Histone modifications are associated with Δ9-tetrahydrocannabinol-mediated alterations in antigen-specific T cell responses.
Yang X; Hegde VL; Rao R; Zhang J; Nagarkatti PS; Nagarkatti M
J Biol Chem; 2014 Jul; 289(27):18707-18. PubMed ID: 24841204
[TBL] [Abstract][Full Text] [Related]
6. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT).
Kaplan BL; Springs AE; Kaminski NE
Biochem Pharmacol; 2008 Sep; 76(6):726-37. PubMed ID: 18656454
[TBL] [Abstract][Full Text] [Related]
7. Differential modulation by delta9-tetrahydrocannabinol (∆9)-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells.
Ngaotepprutaram T; Kaplan BL; Crawford RB; Kaminski NE
J Neuroimmune Pharmacol; 2012 Dec; 7(4):969-80. PubMed ID: 22851303
[TBL] [Abstract][Full Text] [Related]
8. Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by Δ(9)-tetrahydrocannabinol in human CD4(+) T cells.
Ngaotepprutaram T; Kaplan BL; Kaminski NE
Toxicol Appl Pharmacol; 2013 Nov; 273(1):209-18. PubMed ID: 23999542
[TBL] [Abstract][Full Text] [Related]
9. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.
Springs AE; Karmaus PW; Crawford RB; Kaplan BL; Kaminski NE
J Leukoc Biol; 2008 Dec; 84(6):1574-84. PubMed ID: 18791168
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction.
Robinson RH; Meissler JJ; Breslow-Deckman JM; Gaughan J; Adler MW; Eisenstein TK
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1239-50. PubMed ID: 23824763
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.
Xie J; Xiao D; Xu Y; Zhao J; Jiang L; Hu X; Zhang Y; Yu L
Oncotarget; 2016 Feb; 7(6):6436-47. PubMed ID: 26824325
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic study of saikosaponin-d (Ssd) on suppression of murine T lymphocyte activation.
Wong VK; Zhou H; Cheung SS; Li T; Liu L
J Cell Biochem; 2009 May; 107(2):303-15. PubMed ID: 19301261
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of functional properties of tetanus antigen-specific T-cell clones by envelope glycoprotein GP120 of human immunodeficiency virus.
Chirmule N; Kalyanaraman VS; Oyaizu N; Slade HB; Pahwa S
Blood; 1990 Jan; 75(1):152-9. PubMed ID: 1967213
[TBL] [Abstract][Full Text] [Related]
14. Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells.
Issekutz AC; Rowter D; Miescher S; Käsermann F
Clin Immunol; 2015 Oct; 160(2):123-32. PubMed ID: 25982320
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling.
Börner C; Smida M; Höllt V; Schraven B; Kraus J
J Biol Chem; 2009 Dec; 284(51):35450-60. PubMed ID: 19858202
[TBL] [Abstract][Full Text] [Related]
16. Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol.
Lu H; Kaplan BL; Ngaotepprutaram T; Kaminski NE
J Leukoc Biol; 2009 Feb; 85(2):322-9. PubMed ID: 18988696
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor.
Buckley NE; McCoy KL; Mezey E; Bonner T; Zimmer A; Felder CC; Glass M; Zimmer A
Eur J Pharmacol; 2000 May; 396(2-3):141-9. PubMed ID: 10822068
[TBL] [Abstract][Full Text] [Related]
18. Δ9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events.
Karmaus PW; Chen W; Kaplan BL; Kaminski NE
J Neuroimmune Pharmacol; 2012 Dec; 7(4):843-55. PubMed ID: 21789506
[TBL] [Abstract][Full Text] [Related]
19. Relationship of aging and cytokines to the immunomodulation by delta-9-tetrahydrocannabinol on murine lymphoid cells.
Snella E; Pross S; Friedman H
Int J Immunopharmacol; 1995 Dec; 17(12):1045-54. PubMed ID: 8964654
[TBL] [Abstract][Full Text] [Related]
20. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.
Kozela E; Juknat A; Gao F; Kaushansky N; Coppola G; Vogel Z
J Neuroinflammation; 2016 Jun; 13(1):136. PubMed ID: 27256343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
